Ultragenyx Pharmaceutical Inc

Individual Patient Compassionate Use of Burosumab

Brief Summary: 
Individual patient expanded access requests may be considered for patients who have no other treatment options
Detailed Description: 

Expanded access may provide access for treatment prior to approval by the local regulatory agency. For full details, please visit the link provided.

EA Type
Individual Patients
X-linked Hypophosphatemia, Tumor-Induced Osteomalacia

Biological: Burosumab
Other Name: UX023
Other Name: Crysvita®
Other Name: KRN23

Eligibility Criteria: 

Inclusion Criteria:


Exclusion Criteria:


Eligibility Gender: 

Early Access

Ultragenyx Pharmaceutical Inc
Kyowa Kirin Co., Ltd.
EA Number: 
Expanded Access, Compassionate Use, XLH, TIO
MeSH Terms: 
Osteomalacia, Familial Hypophosphatemic Rickets, Hypophosphatemia, Antibodies, Monoclonal
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.